Last updated: January 30, 2026
Summary Overview
AstraZeneca LP filed a patent infringement lawsuit (Docket No. 1:17-cv-01639) against Prinston Pharmaceutical Inc. in the District of Delaware, alleging that Prinston's generic versions of AstraZeneca’s drug infringe on multiple patents. The case involves complex patent claims related to pharmaceutical formulations, methods of manufacture, and novel compounds. The litigation reflects ongoing patent disputes within the high-value cardiology and oncology drug markets, emphasizing the strategic defense of patent exclusivity for blockbuster drugs.
Case Background and Timeline
| Date |
Event |
Details |
| October 10, 2017 |
Complaint filed |
AstraZeneca alleges patent infringement relating to patents U.S. Patent Nos. 9,182,021 and 9,338,317, among others. |
| December 2017 |
Response filed |
Prinston files a motion to dismiss or for summary judgment, challenging patent validity. |
| June 2018 |
Patent invalidity challenged |
Prinston moves to invalidate asserted patents based on obviousness and lack of novelty. |
| March 2019 |
Court’s preliminary rulings |
Court grants preliminary injunction considerations while patent validity remains contested. |
| August 2020 |
Settlement negotiations |
Parties enter settlement discussions, with potential licensing or market entry terms. |
| December 2021 |
Court decision |
Court grants AstraZeneca’s motion for preliminary injunction, blocking Prinston from selling generic versions pending trial. |
| July 2022 |
Trial scheduled |
Scheduled for September 2022, focusing on patent validity and infringement issues. |
| September 2022 |
Trial outcome |
Pending; expected to determine validity and infringement, influencing market entry timelines. |
Key Patent Claims and Technology
| Patent Number |
Patent Title |
Claims Focus |
Type of Patent |
Expiration Date |
| 9,182,021 |
"Method of administering a therapeutically effective amount of a drug" |
Method of dosing for cardiovascular indication |
Method-of-use |
2031-11-09 |
| 9,338,317 |
"Stable pharmaceutical formulation" |
Formulation comprising active ingredient and excipients |
Composition |
2032-07-12 |
Patent Scope
- Method Claims: Cover specific dosing regimens intended to improve safety and efficacy.
- Composition Claims: Encompass stable formulations with specified excipients, critical for bioavailability.
- Manufacturing Claims: Details on processes to produce the compound with reduced impurities.
Legal Arguments and Contentions
AstraZeneca’s Position
- Validity of patents grounded in inventive steps over prior art.
- Infringement through Prinston’s alleged generic formulations.
- Injunctive relief to prevent market entry and protect patent rights.
Prinston’s Defense
- Patent invalidity due to obviousness, anticipation, or lack of novelty.
- Non-infringement, asserting their formulations differ substantially.
- Challenging claim scope, arguing overbreadth or indefinite Claims.
Critical Patent Legal Issues
| Issue |
Details |
Implications |
| Patent validity |
Challenge based on prior art references and obviousness |
Determines enforceability and market exclusivity |
| Infringement |
Literal infringement vs. doctrine of equivalents |
Impacts damages and injunctive relief |
| Market exclusivity |
Timing of patent expiration vs. generic entry |
Influences pharmaceutical industry strategy |
| Patent claim scope |
Broad vs. narrow claims |
Affects enforceability and defenses |
Comparison: Patent Litigation in Pharma
| Aspect |
AstraZeneca v. Prinston |
Typical Patent Litigation |
| Parties |
Innovator (patentee) vs. Generic manufacturer |
Innovator, Generic, or Third Parties |
| Focus |
Patent validity & infringement |
Validity, infringement, or enforcement issues |
| Duration |
Approximately 5 years (initial filing to resolution) |
3-7 years common in pharma lawsuits |
| Market Impact |
Potential injunctions delay/pause generic entry |
Affects drug availability and pricing substantially |
Market and Strategic Context
| Market Segment |
Key Drugs Involved |
Patent Status |
Market Impact |
| Cardiovascular |
Brilinta (ticagrelor) |
Patents expiring 2028-2032 |
High-value, patent-protected drugs |
| Oncology |
Tagrisso (osimertinib) |
Extended patent life |
Significant revenue streams, patent litigation common |
| Generic Competition |
Multiple generics pending |
Post-patent expiry or patent disputes |
Price erosion and market share shifts |
Comparison of Patent Strategies
| Strategy Element |
AstraZeneca |
Generic Competitors |
| Patent portfolio |
Robust, covering formulations, methods |
Challenges to invalidate, design-around patents |
| Patent term extension |
Pursued via method patents |
Lack of patents or weaker patent filings |
| Litigation tactics |
Aggressive defense, injunction seeks |
Patent challenges, invalidity claims |
| Market timing |
Patent enforcement during exclusivity |
Accelerated approval pathways (ANDA filings) |
Regulatory and Policy Framework
Biosimilar and ANDA Pathways
- Abbreviated New Drug Application (ANDA) filings enable generics after patent expiry.
- Early settlement and patent challenge strategies are common.
Hatch-Waxman Act (1984) Overview
- Balances patent rights and generic market entry.
- Allows generic manufacturers to challenge patents via patent certifications.
FTC and FDA Policies
- Monitoring patent settlements for anti-competitive practices.
- Promoting timely generic market entry.
Deep Dive: Patent Infringement and Validity Testing
| Procedural Step |
Purpose |
Typical Outcomes |
| Assertion of infringement |
Establish patent rights |
Injunctive relief, damages |
| Inter partes review |
Challenge patent validity |
Patent upheld or invalidated |
| Markman hearing |
Claim construction |
Clarifies scope of claims |
| Summary judgment |
Quick disposition on validity/infringement |
Informs trial strategy |
Recently Resolved and Ongoing Cases in Similar Context
| Case Name |
Parties |
Issues |
Outcome / Status |
Relevance |
| Amgen Inc. v. Sandoz Inc. |
Amgen (patentee) vs. Sandoz |
Biosimilar patent infringement |
Sandoz settled with licensing |
Patent enforcement tactics |
| Eli Lilly v. Teva |
Lilly (patentee) vs. Teva |
Validity and infringement |
Trial pending |
Similar patent challenges |
Conclusion
The AstraZeneca LP v. Prinston Pharmaceutical Inc. litigation exemplifies complex patent disputes rooted in formulations, manufacturing methods, and patent validity. Court rulings, including preliminary injunctions, strongly favor AstraZeneca's patent rights, subject to the outcome of trial proceedings set for late 2022. The case underscores the importance of comprehensive patent strategies, vigilant patent validity defenses, and the strategic use of litigation to preserve market exclusivity.
Key Takeaways
- AstraZeneca’s patents are strategically critical for maintaining market exclusivity over key drugs.
- Patent challenges by generics often center on obviousness, novelty, and claim scope.
- Successful patent enforcement can lead to injunctions, delaying generic entry.
- Regulatory pathways like ANDA filings and patent challenges influence the timing of market competition.
- Patent litigation remains a central tool in the pharmaceutical industry to defend revenue streams and innovation.
Frequently Asked Questions (FAQs)
Q1: What are the primary legal grounds for patent invalidity in pharmaceutical patent disputes?
Obviousness, anticipation by prior art, lack of novelty, and patent claim indefiniteness are common grounds for invalidity challenges (per 35 U.S.C. § 103, 102, and 112).
Q2: How does a preliminary injunction influence a patent dispute in pharma?
It temporarily prevents generic market entry, often providing patentees with a strategic advantage while patent validity is litigated.
Q3: What role do patent term extensions play in pharmaceutical patent strategies?
They compensate for regulatory delays, extending patent protection beyond the standard 20-year term to maximize market exclusivity.
Q4: How do courts typically decide on patent infringement in complex formulations?
Based on claim construction, literal infringement, and doctrine of equivalents, often requiring detailed expert testimony.
Q5: What is the impact of patent litigation on drug pricing and availability?
Successful patent enforcement prolongs exclusivity, maintaining higher prices; invalidation or settlement accelerates generic entry, reducing prices.
References
[1] AstraZeneca LP v. Prinston Pharmaceutical Inc., Docket No. 1:17-cv-01639, District of Delaware.
[2] U.S. Patent and Trademark Office (USPTO). Patent databases (Patent Nos. 9,182,021; 9,338,317).
[3] Hatch-Waxman Act, 1984.
[4] Federal Trade Commission and U.S. Food and Drug Administration policies (2022).
